Natalija Budimir

Join this workshop to navigate the engineering trade‑offs required to unlock the potential of costimulatory engagers in solid tumors.

• Identifying tumor types, antigen contexts, and safety-limited targets where conditional activation can meaningfully expand the therapeutic window beyond conventional TCE formats
• Evaluating masking, protease-activated, pH/TME-responsive, and multi-layer conditional strategies across TCE architectures, including effects on efficacy, cytokine release, and durability of conditional control in vivo
• Designing robust tumor-localized activation mechanisms by optimizing linker choice, protease specificity, molecular stability, and responsiveness to heterogeneous tumor microenvironments
• Defining the mechanistic and pharmacological requirements for durable conditional control, including activation kinetics, dosing frequency, PD windows for T-cell killing, and risks of tumor adaptation
• Establishing the translational, clinical, and developability bar needed to justify conditional TCE complexity, from PK/exposure and biomarker strategies to trial design, manufacturability, regulatory expectations, and the extent of therapeutic index improvement